[Background] Medical staff have many occasions to be exposed to anticancer drugs (ACDs) in the process of performing cancer chemotherapy. Although guidelines for the safe handling of ACDs have been published, actual measures against exposure to ACDs differ between hospitals, and no surveillance data regarding the conditions of each hospital in relation to performing cheHow to cite this paper: Shirakawa, T.,
Introduction
Cancer is one of the leading causes of morbidity and mortality worldwide [1] . In 2014, malignant neoplasms were responsible for 368,103 deaths, making it the most common cause of death in Japan [2] . The number of deaths due to malignant neoplasms has been increasing, and this trend is expected to continue. Based on recent progress in cancer chemotherapy, a variety of new anticancer drugs (ACDs) have been developed; however, this has led to an increasing chance of exposure to ADCs for medical staff such as doctors, nurses, and pharmacists.
The widely used concept of hazardous drugs (HDs) was first proposed in 1990
by the American Society of Health-System Pharmacists [3] . In 2004, the National
Institution of Occupational Safety and Health (NIOSH) implemented what is
referred to as the "NIOSH Alert" to increase awareness regarding exposure to HDs [4] . ACDs are considered HDs, and ACDs in the wider sense include cytotoxic drugs, molecular-targeted agents, hormonal therapy drugs and immunotherapeutic agents. Adverse events resulting from occasional exposure to ACDs are classified as biological and health influences [5] [6] [7] [8] [9] . Occupational exposure mainly occurs in the preparation, transportation, administration and disposal processes, and various types of occupations are associated with each process. Therefore, the importance of taking measures to prevent occasional ACD exposure has been recognized.
In the U.S., guidelines for the proper handling of ACDs were published by the Occupational Safety and Health Administration in 1986 [10] , the American So- 
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ciety of Health-System Pharmacists (ASHP) in 1990 [3] , the Oncology Nursing Society in 2003 [5] , NIOSH in 2004 [4] , and the International Society of Oncology Pharmacy Practitioners in 2007 [11] . In addition, both the Japan Society of Hospital Pharmacists and the Japan Nursing Association have discussed ways of handling, and taken measures against ACD exposure since 1991. Furthermore, the Ministry of Health, Labour and Welfare in Japan established an additional medical fee in 2010 when hospitals started using a closed-system drug transfer device (CSTD) in preparation for ACDs.
This background shows that measures against ACD exposure among medical staff have been promoted, and this has led to increased awareness in Japan. However, the actual condition of measures against ACD exposure in each hospital that performs cancer chemotherapy in Japan remains unclear because no surveillance data have been available, especially in the English literature. Therefore, we conducted a questionnaire survey regarding the current condition of measures against ACD exposure in cancer chemotherapy and compared the results from 2015 with those from 2012.
Methods

Survey Participants
We conducted a questionnaire survey on medical doctors, pharmacists, nurses and lawyers from 10 hospitals in the Kyushu and Yamaguchi region that are part of the multidisciplinary Fukuoka Medical Oncology Group-Kyushu Yamaguchi Total Oncology Group (FMOG-KYTOG). In these 10 hospitals, patients receive cancer chemotherapy as inpatients or outpatients. Responses were received from all 10 hospitals, which included two core prefectural hospitals and six core local hospitals. Multiple choice questions were used to help eliminate potential sources of bias and arbitrariness. All participants were informed that their participation in the present study was voluntary. Certified specialists, including medical oncologists, clinical pharmacists, and nurses, were selected to participate. The number of participating hospitals differed in each survey because the sample size was based on the number of participants in the FMOG-KYTOG who were able to respond to the survey.
Survey Timing
The first survey was conducted in February 2012 on pharmacists from eight FMOG-KYTOG hospitals as an actual condition survey regarding measures against exposure to ACDs in preparing for injections. The second survey was conducted in May 2012 on doctors and nurses from 18 divisions in six FMOG-KYTOG hospitals regarding measures against exposure to ACDs during administration. The final survey was conducted in August 2015 on nurses and pharmacists from 10 FMOG-KYTOG hospitals regarding measures against exposure to ACDs during administration and the current conditions and problems of the ambulatory treatment unit (ATU). About 15 participants were enrolled in each survey.
Survey Contents
Question items in the survey regarding preparation for ACD injections concerned the following: ACD preparation conditions (subjects, cases, occupations, holiday correspondence, environment and devices), measures against ACD exposure during preparation, abolition conditions, and cleaning conditions at the facility. Question items regarding the administration of ACD injections concerned the following: hospital manuals, means of conveyance, equipment, use of tools or goods, abolition conditions, and how to deal with patients. Question items regarding the actual current conditions and problems of the ATU concerned the following: current conditions and hopes of the ATU, administration equipment, use of tools or goods, abolition conditions, and preparation by pharmacists. The contents of survey were not standardized. The validity and reliability of the questionnaire were not tested, so the questions, statements, and answers were constructed and revised by certified specialists. 
Results
Survey of pharmacists regarding measures against exposure during preparation for ACD injections in 2012.
Preparation for ACD Injections and Number of Monthly Cases
The current conditions regarding preparation for ACD injections by pharmacists within one month in 2012 were surveyed. Answers were collected from pharmacists in all eight of the participating hospitals (response rate, 100%).
Pharmacists prepared ACDs for all patients in seven hospital outpatient and six hospital inpatient departments. Pharmacists from other hospitals also prepared ACDs for most of the patients. Pharmacists from four hospitals prepared ACDs on holidays. In these four hospitals, ACD preparation was only performed by pharmacists. ACDs were occasionally prepared by doctors at four hospital inpatient departments, and by nurses at one hospital outpatient department. The numbers of cases involving ACD preparation at all hospital inpatient and outpatient departments are shown in Table 1 .
Condition of the Environment and Equipment during Preparation or Audit
Environmental factors for the preparation of ACDs were surveyed (Table 1) .
ACDs were prepared in an exclusive room in the department of pharmacy within all hospitals. Preparation involved the use of class II biological safety cabinets (BSCs) in all hospitals. Seven hospitals used an exhaust system for outside ventilation. During preparation, masks, gowns, and gloves were used in all hospitals. BSC, biological safety cabinet; CSTD, closed-system drug transfer device; *, multiple answers allowed.
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Three hospitals also used hair covers, and two others used goggles. Double-use of gloves made of nitrile, latex, or plastic was used in seven hospitals. A CSTD was used during ACD preparation in five hospitals, and the types of drugs used were cyclophosphamide, ifosfamide, and bendamustine. ACDs were recapped or exhausted during weighing in all and seven hospitals, respectively. All hospitals exhausted glass vials and ampuls of ACDs into sealed plastic bags after preparation. ACDs were exhausted into exclusive containers in all hospitals. Pharmacists in one hospital primed ACDs, pharmacists in another hospital used gloves and masks during the auditing process, and two other hospitals used gloves.
Cleaning Environment
Cleaning was performed every day in all hospitals (Table 1) . Alcohol was used for cleaning BSCs in all hospitals, and wet wiping (wiping after being soaked in water) was additionally performed in four hospitals. Idling of BSCs was performed before and after use in six hospitals. The floor of the preparation room was cleaned in six hospitals: wet wiping was used in five hospitals and dry-cloth wiping was used in one. Moreover, 0.3% sodium hydroxide was used in one hospital.
Survey of doctors and nurses regarding measures against exposure during ACD administration in outpatients in 2012.
Measures against Exposure during Conveyance or Administration of ACDs
Answers were collected from clinical oncologists or pharmacists in all six of the participating hospitals (response rate, 100%). Manuals regarding measures against exposure were used in four hospitals ( Table 2) . Conveyance of ACD injections after preparation was conducted by staff in charge of conveyance in four hospitals. Pharmacists in two hospitals, nurses in two hospitals, and nurse aids in one hospital were also engaged in conveyance work. All hospitals had original conveyance measures against exposure. Five hospitals used exclusive containers. Syringe caps and plastic bags were used in four hospitals each. A CSTD was used during ACD administration in patients in only one hospital. Medical staff in five hospitals used gloves during administration. Surgical masks were used in all hospitals, and goggles were used in one. Personal protective equipment (PPE) was exchanged before every patient treatment in four hospitals. Back-priming was carried out during administration in four hospitals. For measures regarding the administration route for ACD injections, gloves were used in one hospital and water-absorbing sheets were used in another. Regarding measures against exposure during ACD bottle exchange, gloves were used in all hospitals, surgical masks were used in five, and goggles were used in two.
Measures against Exposure for Patients and Their Families after ACD Administration
ACD bottles after administration were placed in sealed plastic bags at one hospital. Adhered ACDs were exhausted within sealed plastic bags and then 
Background of Chemotherapy in Outpatients and ACD Preparation
Current conditions for the medical staff concerning chemotherapy in outpatient departments were surveyed in all 10 of the participating hospitals (response rate, 100%). Table 3 shows the number of beds used for chemotherapy in outpatient departments, the daily mean number of patients receiving chemotherapy, and the total number of nurses ( Table 3 ). As part of outpatient services, ACDs were prepared for all cases receiving chemotherapy by hospital pharmacists. As part of inpatient services, ACDs were prepared for all cases by hospital pharmacists in eight hospitals. ACDs were prepared by doctors in five hospitals and by nurses in two.
Measures against Exposure during Conveyance or Administration of ACDs
Eight hospitals used CSTDs during ACD administration. The types of drugs used were cyclophosphamide (seven hospitals), bendamustine (six hospitals), and ifosfamide (four hospitals). Surgical masks and nitrile gloves were used as PPE during administration in all hospitals. Goggles were used in one hospital.
PPE exchange was conducted for every patient in seven hospitals. Back-priming at administration was done in nine hospitals, and the types of ACDs used were cyclophosphamide, ifosfamide, bendamustine, bevacizumab, trastuzumab and pertuzumab. When connecting ACD infusion lines or preparing for intravenous administration, four hospitals took measures against exposure: two used cotton pads soaked with alcohol, and two used water-absorbing sheets. Ten hospitals took measures against exposure such as PPE use (five hospitals) and working in a low position (five hospitals) during ACD bottle exchange.
Measures against Exposure after Administration of ACDs
After administration, ACD bottles were placed in sealed plastic bags in eight hospitals. Adhered ACDs were exhausted within sealed plastic bags and placed in penetration-resistant containers in eight hospitals.
Comparison of results from 2012 and 2015 Water-absorbing sheet 2 20
Nothing special 5 50
Measures against exposure at ACD bottle exchange* Use of PPE 5 50
Work at low position 5 50
Other 2 20
Conveyance of ACDs within a sealed plastic bag after administration 8 80
Drug exhausion within a sealed plastic bag into a penetration-resistent container 8 80
ACD, anticancer drug; BEN, bendamustine; CPA, cyclophosphamide; CSTD, closed-system drug transfer device; IFM, ifosfamide; PPE, personal protective equipment. *, multiple answers allowed, except for injection into the spinal space.
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The results for 10 survey items in 2012 were compared with those from 2015 (Table 4) 
Discussion
We conducted a questionnaire survey regarding the current conditions against exposure to ACDs and compared the results between 2012 and 2015. In both years, ACDs were prepared by pharmacists in all hospitals. According to existing guidelines, one central section of the hospital is required for the preparation of ACDs [10] , and medical staff engaged in ACD preparation should comprise pharmacists and either a doctor or a nurse with special training [11] . The guidelines recommend the use of class II type B2 BSCs as opposed to type A2 BSCs in [13] . It also reduces the contamination of infusion lines by cyclophosphamide, ifosfamide, and fluorouracil [14] in BSCs, on the floor, and in workstations [15] . Since the use of CSTDs in all occasions is difficult, it is desirable to carry out back-priming, which is a way of bypassing the main infusion route. Infusion tubes with lock-type connections or that cover part of the connection with gauze during exchange of ACDs are also important.
The active use of CSTDs or back-priming might be important for exposure prevention.
In and face shields are used to protect the eyes and face from ACD exposure, as are hair and shoe covers [3] [10] [11] . Based on the results of this survey, surgical masks and gloves were used during administration and gowns were worn during preparation in all hospitals. Although the use of these tools is considered necessary, the costs can become high if N95 masks, goggles, and gowns are used at every administration, and this therefore needs to be taken into consideration. It is also important to remember to use expanded plastic or other proper containers for transporting ACDs after preparation to prevent leakage or breakage [5] [11].
The publication of manuals or guidelines was expected to be useful during conveyance and disposal of ACDs because the rates of conveyance and disposal of ACDs within sealed plastic bags after administration before being placed into penetration-resistant containers was markedly improved in 2015 from 2012 [12] [17]. Although the publication of a manual has been shown to improve the conveyance of ACDs within plastic sealed bags after administration [12] , no special legal restrictions are currently in place for the abolition of contaminated ACDs or PPE in Japan. As realistic measures against exposure, abolitions should be placed into sealed plastic bags and then disposed in exclusive boxes for ACDs [3] . PPE should also be discarded in the same manner before hand washing with soap and water [4] . Abolition should be carried out using masks and gloves [4] [5]. However, each hospital needs to formulate their own regulations in relation to these and other problems, such as the handling of excreta, dirty linens, and body fluids. Currently, more cases are seen in which ACDs are administrated at home through central venous ports; therefore, measures against exposure should be provided in advance, similar to medical staff, to patients and their families to help prevent needless exposure.
To our knowledge, this is the first report concerning the actual conditions against exposure to ACDs in Japan. However, the present study does have some limitations. First, the sample size was small, which may have limited the interpretation of the data. We hope to conduct a subsequent study with a larger sample size in the future. Second, the present survey was conducted in core hospitals for cancer therapy, which raises the possibility that disparities between hospitals in Japan might not be adequately reflected. Third, the questionnaire method employed in the present study possesses a potential limitation in terms of the reliability of the measurements. We therefore compared survey results obtained at different times and found that the data were similar.
In conclusion, we report surveillance data regarding the current conditions of measures against ACD exposure in core hospitals for cancer chemotherapy in Japan. The findings illuminated difficulties in strictly following the guidelines, and suggested that the measurement of ACD exposure needs to be improved.
Publishing appropriate manuals and providing adequate education for medical staff in every institution in Japan could be expected to improve this situation.
